We report a case of fingolimod-associated bilateral cystoid macular oedema in a patient with multiple sclerosis (MS). A 34-year-old female, diagnosed with MS at age of 30, developed bilateral blurred vision 5 days after initiation of fingolimod. She was misdiagnosed as optic neuritis initially and fingolimod was only discontinued 3 weeks after onset of her visual symptoms when OCT showed prominent bilateral cystoid macular oedema and subretinal fluid. Although her left corrected vision returned to 6/6, she had persistently decreased right visual acuity of 6/12 after 5 months. This paper aims to raise awareness among ophthalmologists and neurologists of the importance of early recognition of macular oedema associated with fingolimod
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system with ...
PURPOSE: Fingolimod is the first oral drug approved for treatment of relapsing-remitting multiple s...
International audienceFingolimod is a widely used treatment for highly active relapsing multiple scl...
Fingolimod 0.5-mg once-daily is an approved therapy for patients with relapsing–remitting multiple s...
AbstractPurposeFingolimod is among the first oral disease-modifying agents for the treatment of rela...
Fingolimod is an oral sphingosine-1-phosphate (S1P) receptor modulator and the first oral therapy fo...
Background: Fingolimod (FNG) is associated with the development of symptomatic macular edema (ME) in...
BACKGROUND: Patients with multiple sclerosis (MS) have a higher incidence of uveitis compared with t...
BACKGROUND: To evaluate the effect of fingolimod in visual function and neuroretinal structures in p...
Multiple sclerosis is a chronic inflammatory disease of central nervous system that commonly affects...
Cystoid macular edema is rarely observed secondary to paclitaxel treatment. A 55-year-old female pat...
Introduction This study aimed to evaluate whether treatment with fingolimod (FTY) may induce functio...
Introduction This study aimed to evaluate whether treatment with fingolimod (FTY) may induce functio...
This is the case report of a multiple sclerosi patient who presented frequent relapses early after b...
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system with ...
PURPOSE: Fingolimod is the first oral drug approved for treatment of relapsing-remitting multiple s...
International audienceFingolimod is a widely used treatment for highly active relapsing multiple scl...
Fingolimod 0.5-mg once-daily is an approved therapy for patients with relapsing–remitting multiple s...
AbstractPurposeFingolimod is among the first oral disease-modifying agents for the treatment of rela...
Fingolimod is an oral sphingosine-1-phosphate (S1P) receptor modulator and the first oral therapy fo...
Background: Fingolimod (FNG) is associated with the development of symptomatic macular edema (ME) in...
BACKGROUND: Patients with multiple sclerosis (MS) have a higher incidence of uveitis compared with t...
BACKGROUND: To evaluate the effect of fingolimod in visual function and neuroretinal structures in p...
Multiple sclerosis is a chronic inflammatory disease of central nervous system that commonly affects...
Cystoid macular edema is rarely observed secondary to paclitaxel treatment. A 55-year-old female pat...
Introduction This study aimed to evaluate whether treatment with fingolimod (FTY) may induce functio...
Introduction This study aimed to evaluate whether treatment with fingolimod (FTY) may induce functio...
This is the case report of a multiple sclerosi patient who presented frequent relapses early after b...
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system with ...
PURPOSE: Fingolimod is the first oral drug approved for treatment of relapsing-remitting multiple s...
International audienceFingolimod is a widely used treatment for highly active relapsing multiple scl...